IonGate Biosciences has launched the SURFE2R Workstation 5000, the company announced this week. This fully integrated screening center is the new flagship model of IonGate’s SURFE2R product family.
The SURFE2R Workstation 5000 allows a 10-fold increase in throughput, compared to the previous model, the SURFE2R 500. As many as 10,000 measurements can be carried out per day. The SURFE2R Workstation 5000 integrates liquid handling units, the detection modules, and a computer, as well as system liquid and waste management units.
Connectivity to other lab automation equipment will be provided in a future enhancement, the manufacturer said.
IonGate will introduce the SURFE2R Workstation 5000 internationally at the Drug Discovery & Development of Innovative Therapeutics conference, to be held next week in Boston, Mass.
Thermo Fisher Scientific announced this week that it has expanded its Thermo Scientific Stem Cell Excellence program.
The expanded Stem Cell Excellence portfolio now includes Thermo Scientific HyClone AdvanceSTEM reagents, kits, and stem cell lines, as well as the Thermo Scientific Dharmacon Accell siRNA reagent for gene silencing, and Nunc cell culture inserts for cell-based assays.
TTP LabTech has introduced the RAPid 4 technology for label-free interactions analysis, the company announced this week.
The RAPid 4 is a flow-based analysis system that uses Resonant Acoustic Profiling technology. The detection of molecular interactions through acoustic technology offers substantial advantages over optical biosensors, according to the manufacturer. It reduces the need to purify samples and generates accurate kinetic, affinity, and concentration measurements from complex biological mixtures, such as blood, serum, cell culture supernatants, and periplasmic extracts.
Exploiting the piezoelectric effects of quartz crystal resonators, the RAPid 4 allows label-free detection of molecular interactions in real time.
RAPid 4 is designed to analyze up to four samples, or combinations of samples, and control materials in parallel. The company said that it typically processes an average of 350 samples per day.
The instrument is a fully automated platform, and runs unattended for up to 72 hours.
BellBrook Labs this week introduced the Transcreener GDP assay, which is dedicated to GDP nucleotide product (KM1) detection.
The Transcreener GDP assay is a far-red, competitive fluorescence polarization immunoassay based on the detection of the diphosphonucleotide product of GTP hydrolysis (not the free phosphate). The assay provides a signal under initial velocity conditions resulting in overall Z’= 0.7, with = 85 mP polarization shifts at 10 percent GTP conversion of 10 µM GTP measured using standard multimode plate readers.
The Transcreener GDP Assay was developed to follow the progress of any enzyme that produces GDP. The Transcreener GDP detection mixture comprises a GDP Alexa633 tracer bound to a GDP antibody. The tracer is displaced by GDP, the invariant product generated during the enzyme reaction. The displaced tracer freely rotates, leading to a decrease in fluorescence polarization. GDP production is thus proportional to a decrease in polarization.